Home › NDC Lookup › RxCUI directory › RxCUI 2476644

Bismuth subsalicylate 262 MG Chewable Tablet [Kaopectate Reformulated Aug 2006] — RxCUI 2476644

RxNorm drug concept · Semantic branded drug
RxCUI 2476644 Semantic branded drug · SBD ● Current RxNorm concept 1 FDA product 2 package NDCs Snapshot Jul 14, 2026

This page is curated, coded, and maintained by

Compiled from public NLM RxNorm and FDA (openFDA NDC directory) data sources. Editorial policy

What you’re looking at: the standardized identity of one medicine, as the U.S. drug-data system sees it. Below — every FDA-listed product, package code, price benchmark, and billing code that maps to it.

🗂️ Key Facts

RxCUI2476644
Official nameBismuth subsalicylate 262 MG Chewable Tablet [Kaopectate Reformulated Aug 2006]
Concept typeSemantic branded drug (SBD)
RxNorm statusCurrent RxNorm concept
Also known asKaopectate Reformulated Aug 2006 262 MG Chewable Tablet
FDA products mapped1
Package NDCs mapped2
RxNorm release07/06/2026
Snapshot dataJul 14, 2026

📖 Skip the Codes — Read It in Plain English.

Our pharmacist-built guide to Bismuth Subsalicylate: what it is, how it’s used, side effects, and interactions.

📗 Our plain-language guide HelloPharmacist
  • It relieves diarrhea, including traveler's diarrhea. It also helps with upset stomach after overindulging in food and drink, such as heartburn, indigestion, nausea, gas, belching a...
  • Use it only until the diarrhea stops, and no more than 2 days. If you're not better by then, or you get worse sooner, stop and see a doctor. Drink plenty of clear fluids while you...
  • That's a known, temporary and harmless effect of this medicine. But black stool can also signal bleeding, so do not use it if you already have bloody or black stool.
  • Children under 12 should be checked by a doctor first. Children and teens who have or are recovering from chicken pox or flu-like symptoms should not use it because of Reye's syndr...
📖 Read our full Bismuth Subsalicylate guide →

🕸️ Concept Web — How Bismuth subsalicylate 262 MG Chewable Tablet [Ka... Connects

One RxCUI never lives alone. Follow the path from the raw ingredient down to the exact strength-and-form concepts FDA products carry — every stop is a real RxNorm concept with its own identifier. Hover or focus any chip for what it means.
This page's concept Bismuth subsalicylate 262 MG Chewable Tablet [Kaopectate Reformulated Aug 2006] RxCUI 2476644

Every web starts here: one RxCUI, one fixed meaning in the RxNorm vocabulary.

  1. Ingredients 1

    The active substance itself — no strength, form, or brand attached yet.

    • Bismuth subsalicylate 19478
  2. Brand names 1

    The same medicine's trade names. A brand name alone says nothing about strength or form.

    • Kaopectate Reformulated Aug 2006 659118
  3. Dose forms 12

    The ingredient poured into a form — tablet, solution, cream — still without one fixed strength.

    • Bismuth subsalicylate Chewable Tablet 371099
    • Bismuth subsalicylate Chewable Product 1294883
    • Bismuth subsalicylate Oral Product 1161839
    • Bismuth subsalicylate Pill 1161840
    • Bismuth subsalicylate Chewable Tablet [Kaopectate Reformulated Aug 2006] 2476642
    • Kaopectate Reformulated Aug 2006 Chewable Product 2476643
    • Kaopectate Reformulated Aug 2006 Oral Product 1169277
    • Kaopectate Reformulated Aug 2006 Pill 1169278
    • +4 more in this family
  4. Clinical & branded drugs 3

    Ingredient + strength + dose form. These are the concepts real FDA products actually carry.

  5. Packs 1

    Fixed collections of drugs packaged and sold together, like dose packs.

    • {112 (bismuth subsalicylate 262 MG Chewable Tablet) / 56 (metronidazole 250 MG Oral Tablet) / 56 (tetracycline hydrochloride 500 MG Oral Capsule) } Pack 758019

Showing up to 8 concepts per family — 14 of 18 stored related concepts drawn.
These are official RxNorm vocabulary relationships — how concepts name and organize the same medicine. They do not establish therapeutic equivalence or substitutability: two concepts appearing in one web is never a statement that products can be swapped.

🔀 Generic ⇄ Brand Crosswalk

The same medicine has an unbranded (generic) identity and one or more brand-name identities — each with its own RxCUI. This is a naming relationship in RxNorm, not a statement that any two products are substitutable.

Generic (Clinical) Concepts

  • Bismuth subsalicylate 262 MG Chewable Tablet SCD · 308761
  • Bismuth subsalicylate 262 MG SCDC · 315491
  • Bismuth subsalicylate Chewable Tablet SCDF · 371099
  • Bismuth subsalicylate Chewable Product SCDG · 1294883
  • Bismuth subsalicylate Oral Product SCDG · 1161839
  • Bismuth subsalicylate Pill SCDG · 1161840
  • {112 (bismuth subsalicylate 262 MG Chewable Tablet) / 56 (metronidazole 250 MG Oral Tablet) / 56 (tetracycline hydrochloride 500 MG Oral Capsule) } Pack GPCK · 758019

Brand-Name Concepts

  • Bismuth subsalicylate 262 MG [Kaopectate Reformulated Aug 2006] SBDC · 642347
  • Bismuth subsalicylate Chewable Tablet [Kaopectate Reformulated Aug 2006] SBDF · 2476642
  • Kaopectate Reformulated Aug 2006 Chewable Product SBDG · 2476643
  • Kaopectate Reformulated Aug 2006 Oral Product SBDG · 1169277
  • Kaopectate Reformulated Aug 2006 Pill SBDG · 1169278
  • Kaopectate Reformulated Aug 2006 BN · 659118

📦 FDA Products & Package NDCs

1 product · 2 package NDCs
2 package NDCs map to RxCUI 2476644 in the current snapshot — up to 50 per page. Each linked NDC opens its full package page.
Package NDC Package Brand / generic name Labeler Marketing start
55505-0206-69 1 BOTTLE in 1 CARTON (55505-206-69) / 24 TABLET, CHEWABLE i... Kaopectate Kramer Laboratories 2021-02-01
55505-0206-79 2 CARTON in 1 PACKAGE (55505-206-79) / 1 BOTTLE in 1 CARTON... Kaopectate Kramer Laboratories 2025-06-01
Observed labelers: Kramer Laboratories (2) — this is the FDA-listed mapping footprint, not sales, inventory, availability, or market share.

🗃️ Sources & Limits

Atlas generation902fddb9-e9c1-4004-bf4c-dba4d51037c7
openFDA export observedJul 14, 2026
RxNorm release07/06/2026
Methodology2026-07-full-catalog-v1
  • A shared RxCUI does not prove interchangeability. Products mapped to the same concept are not thereby equivalent or substitutable — equivalence is a separate, product-level determination.
  • Listing here does not establish approval or coverage. Appearing in this snapshot is a data observation, not an FDA approval status or a payer coverage decision.
  • Missing data never means zero. A silent dataset (no price, no billing code, no utilization) means no observation — not that the real-world value is zero.
  • Counts describe the mapping footprint. Product, package, and labeler counts are the FDA-listed mapping footprint in this snapshot — not sales, inventory, availability, or market share.
This product uses publicly available data from the U.S. National Library of Medicine (NLM), National Institutes of Health, Department of Health and Human Services; NLM is not responsible for the product and does not endorse or recommend this or any other product.

Machine-readable JSON

Reference information about drug-concept identifiers and public regulatory data — not medical advice. Talk to your pharmacist or prescriber about your own medication.